- B11 -

Home The FDA has approved suzetrigine Journavx Vertex a selective sodium channel blocker for oral treatment of moderate to severe acute pain in adults. Suzetrigine is the first sodium channel blocker to be approved in the US for this indication and the first oral nonopioid drug to be approved for treatment of pain in over 25 years. STANDARD TREATMENT Nonopioid drugs are preferred for treatment of pain. In patients with moderate to severe acute pain use of an NSAID plus acetaminophen may be at least as effective as an oral opioid combined with acetaminophen or even an injected opioid.